|
Malignant neoplasm of breast
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
A novel histone H4 variant H4G regulates rDNA transcription in breast cancer.
|
31219579 |
2019 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
In total, we identify and quantify 233 proteoforms of histone H4 in two breast cancer cell lines.
|
29667342 |
2018 |
|
Malignant neoplasm of breast
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This approach is validated on different types of samples, including formalin-fixed paraffin-embedded pathology tissues, and employed to profile histone H4 modifications in cancer samples and normal tissues, identifying previously reported differences, as well as novel ones.
|
30471193 |
2019 |
|
Malignant Neoplasms
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
In the lungs, acrylamide exposure resulted in a decrease of histone H4 lysine 20 trimethylation (H4K20me3), a common epigenetic feature of human cancer, while in the livers, there was increased acetylation of histone H3 lysine 27 (H3K27ac), a gene transcription activating mark.
|
30807115 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
In the lungs, acrylamide exposure resulted in a decrease of histone H4 lysine 20 trimethylation (H4K20me3), a common epigenetic feature of human cancer, while in the livers, there was increased acetylation of histone H3 lysine 27 (H3K27ac), a gene transcription activating mark.
|
30807115 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
This approach is validated on different types of samples, including formalin-fixed paraffin-embedded pathology tissues, and employed to profile histone H4 modifications in cancer samples and normal tissues, identifying previously reported differences, as well as novel ones.
|
30471193 |
2019 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Abbreviations: ALS: Amyotrophic Lateral Sclerosis; APP: Amyloid Precursor Protein gene; CASP3: Caspase 3 gene; CASP9: Caspase 9 gene; H2AFX: H2A histone family, member X gene; HIST1H2AL: Histone H2A type 1 gene; HIST1H2BK: Histone H2B type 1-K gene; HIST1H3J: Histone H3J gene; HIST1H4B: Histone H4B gene; HIST2H2BE: Histone H2B type 2-E gene; HUGO: human genome organization; KM: Kaplan-Meier survival curve; MAPT: Tau gene; OV: Ovarian cancer; SNCA: alpha-syneculin gene; TARDBP: Transactive response DNA binding protein 43 kDa; TCGA: the cancer genome atlas.
|
30394813 |
2018 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Methylation of histone H4 lysine 20 (H4K20) has been associated with cancer.
|
29616094 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Methylation of histone H4 lysine 20 (H4K20) has been associated with cancer.
|
29616094 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Abbreviations: ALS: Amyotrophic Lateral Sclerosis; APP: Amyloid Precursor Protein gene; CASP3: Caspase 3 gene; CASP9: Caspase 9 gene; H2AFX: H2A histone family, member X gene; HIST1H2AL: Histone H2A type 1 gene; HIST1H2BK: Histone H2B type 1-K gene; HIST1H3J: Histone H3J gene; HIST1H4B: Histone H4B gene; HIST2H2BE: Histone H2B type 2-E gene; HUGO: human genome organization; KM: Kaplan-Meier survival curve; MAPT: Tau gene; OV: Ovarian cancer; SNCA: alpha-syneculin gene; TARDBP: Transactive response DNA binding protein 43 kDa; TCGA: the cancer genome atlas.
|
30394813 |
2018 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In normal RWPE-1 cells and even stronger in cancer DU145 cells, the combined treatment induced both AR gene expression on the mRNA level and increased histone H4 acetylation in AR gene promoter.
|
27499010 |
2016 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In normal RWPE-1 cells and even stronger in cancer DU145 cells, the combined treatment induced both AR gene expression on the mRNA level and increased histone H4 acetylation in AR gene promoter.
|
27499010 |
2016 |
|
Malignant Neoplasms
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
The genome-wide loss of histone H4 lysine 20 tri-methylation (H4K20me3) is observed in multiple types of cancer, including breast tumors.
|
25814362 |
2015 |
|
Primary malignant neoplasm
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
The genome-wide loss of histone H4 lysine 20 tri-methylation (H4K20me3) is observed in multiple types of cancer, including breast tumors.
|
25814362 |
2015 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Alterations in histone H4 lysine 20 methylation: implications for cancer detection and prevention.
|
22035019 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Alterations in histone H4 lysine 20 methylation: implications for cancer detection and prevention.
|
22035019 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Global profiling of histone changes in some human cancers demonstrated that loss of histone H4 acetylation at lysine16 (H4KA16) and trimethylation at lysine 20 (H4KM20) was a common hallmark of cancer.
|
21415707 |
2011 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Global profiling of histone changes in some human cancers demonstrated that loss of histone H4 acetylation at lysine16 (H4KA16) and trimethylation at lysine 20 (H4KM20) was a common hallmark of cancer.
|
21415707 |
2011 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.
|
15765097 |
2005 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.
|
15765097 |
2005 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Beside H4K20me3, plasma histone H4 is a useful marker to discriminate colonic tumors from precancerous polyps and other conditions.
|
31471419 |
2020 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Glioma-induced SIRT1-dependent activation of hMOF histone H4 lysine 16 acetyltransferase in microglia promotes a tumor supporting phenotype.
|
29308302 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Further, we demonstrate that the observed hypo-acetylation of histone H4 in tissue and serum samples of tumor bearing animals corroborated with the elevated HDAC activity in both samples compared to normal.
|
28360947 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Whereas the levels of H4 and histone acetyltransferases were stable irrespective of HRD status, the levels of histone H4 acetylation and one HDAC, HDAC6, were elevated in the HRD tumors.
|
28866885 |
2017 |